China Imposes 362 Million Yuan Fine for Pharmaceutical Monopoly
China Imposes 362 Million Yuan Fine for Pharmaceutical Monopoly
China Imposes 362 Million Yuan Fine for Pharmaceutical Monopoly
Source: Qualcomm official WeChatOn February 25, 2025, the U.S. 9th Circuit Court of Appeals issued a ruling in a consolidated antitrust class action lawsuit against Qualcomm, affirming the district court's dismissal of plaintiffs' claims that Qualcomm's "no license, no chips" p
On December 9, 2024, China's State Administration for Market Regulation("SAMR") issued a public notice announcing that it would initiate a case to investigate NVIDIA's suspected monopolization due to alleged violations of the Anti-Monopoly Law of China.
On November 8, China’s top market regulator, the State Administration for Market Regulation (SAMR), issued the "Antitrust Guidelines for Standard Essential Patents" (hereinafter referred to as the "Guidelines"). The Guidelines consist of six chapters and 22 articles.
On June 18, China released the "Annual Report on China's Anti-Monopoly Enforcement (2023)". The report shows that in 2023, 27 cases involving monopoly agreements and abuse of market dominance were penalized, with total fines and confiscations of 2.163 billion yuan.